Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

New England Journal of Medicine

Volumn 353, Issue 16, 2005, Pages 1673-1684

  Romond, Edward H ^a,b   Perez, Edith A ^c,d   Bryant, John ^a,e   Suman, Vera J ^c,f   Geyer Jr , Charles E ^a,g,s   Davidson, Nancy E ^h   Tan Chiu, Elizabeth ^a,i   Martino, Silvana ^j   Paik, Soonmyung ^a   Kaufman, Peter A ^k   Swain, Sandra M ^a,l   Pisansky, Thomas M ^c,f   Fehrenbacher, Louis ^a,m   Kutteh, Leila A ^c,n   Vogel, Victor G ^a,o   Visscher, Daniel W ^c,f   Yothers, Greg ^a,e   Jenkins, Robert B ^f   Brown, Ann M ^a   Dakhil, Shaker R ^c,p   Mamounas, Eleftherios P ^a,q   Lingle, Wilma L ^c,f   Klein, Pamela M ^r   Ingle, James N ^c,f   Wolmark, Norman ^a,g   more..

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c North Central Cancer Treatment Group Rochester   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f MAYO CLINIC   (United States)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ Cancer Research Network   (United States)

^j Angeles Clinic and Research Institute   (United States)

^k DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m KAISER PERMANENTE   (United States)

ⁿ Cedar Rapids Oncology Project CCOP   (United States)

^o UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^p WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^q Aultman Health Foundation   (United States)

^r GENENTECH INC   (United States)

^s Allegheny Cancer Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; LUNG INFILTRATE; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; MASTECTOMY; MIDDLE AGED; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECURRENCE; SURVIVAL ANALYSIS;

EID: 26844536978     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa052122     Document Type: Article

References (16)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-8.
4. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37:849-57.
5. Pocock SL, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
6. Albain KS, Green S, Ravdin P, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from North American Intergroup Trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002;21:37A abstract.
7. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. [Erratum, Lancet 2002;360:1520.]
8. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 2001;322:1479-80.
9. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7.
10. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43.
11. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
13. Ewer MS, Vooletich M, Valero V, Higano CS, Benjamin RS. Trastuzumab (Herceptin) cardiotoxicity: clinical course and cardiac biopsy correlations. Proc Am Soc Clin Oncol 2002;21:123A. abstract.
14. Tan Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide (AC) followed by paclitaxel (2AC) followed by paclitaxel plus trastuzumab as adjuvant therapy for patients with node-positive HER2-overexpressing breast cancer. J Clin Oncol (in press).
15. Perez EA, Suman VJ, Davidson N, et al. HER2 testing by local, central and reference laboratories in the NCCTG N9831 trial. Available at http://asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-005815,00.asp.
16. Piccart-Gebhart M. A randomized threegroup multi-centre comparison of: 1 year Herceptin, 2 years Herceptin, or no Herceptin, in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy. Available at http://asco.org/ac/1,1003,_12-002511-00_18-0034_19-005816,00.asp.